Journal article
Menopausal hormone therapy: assessing associations with breast and colorectal cancers by familial risk
RJ MacInnis, MA Jenkins, RL Milne, EM John, MB Daly, IL Andrulis, SV Colonna, KA Phillips, K Investigators, LL Le Marchand, PA Newcomb, AI Phipps, SL Schmit, FA Macrae, DD Buchanan, S Gallinger, RK Pai, NJ Samadder, GG Giles, MC Southey Show all
Jnci Cancer Spectrum | OXFORD UNIV PRESS | Published : 2025
Open access
Abstract
Menopausal users of hormone replacement therapy (HRT) are at increased breast cancer risk and decreased colorectal cancer (CRC) risk compared with individuals who have never used HRT, but these opposing associations may differ by familial risk of breast cancer and CRC. We harmonized data from 3 cohorts and generated separate breast cancer and CRC familial risk scores based on cancer family history. We defined moderate or strong family history as a risk score of 0.4 or higher, where 0.4 was equivalent to a 50-year-old woman with 1 parent diagnosed with either breast cancer or CRC at 55 years of age. Of 24 486 women assessed, 1243 and 405 were diagnosed with incident breast cancer and CRC, res..
View full abstractRelated Projects (1)
Grants
Awarded by National Breast Cancer Foundation
Funding Acknowledgements
We would like to thank all the investigators, staff, and participants of the Breast Cancer Family Registry. We wish to thank all the The Kathleen Cuningham Foundation Consortium for Research into Familial Aspects of Breast Cancer (kConFab) research nurses and staff, the heads and staff of the Family Cancer Clinics, and the Clinical Follow Up Study (which has received funding from the National Health and Medical Research Council, the National Breast Cancer Foundation, Cancer Australia, and the US National Institutes of Health [NIH]) for their contributions to this resource and the many families that contribute to kConFab. The CCFR graciously thanks the generous contributions of its study participants, the dedication of study staff, and the financial support from the US National Cancer Institute (NCI), without which this important registry would not exist. We thank the original MCCS investigators and the diligent team that recruited the participants and continue working on follow-up, for their contribution. We also express our gratitude to the many thousands of Melbourne residents who continue to participate in the study. The MCCS cohort recruitment was funded by Cancer Council Victoria (https://www.cancervic.org.au/) and VicHealth (https://www.vichealth.vic.gov.au/).